Last reviewed · How we verify
Vitamin-K antagonist at INR 2-3 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Vitamin-K antagonist at INR 2-3 (Vitamin-K antagonist at INR 2-3) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vitamin-K antagonist at INR 2-3 TARGET | Vitamin-K antagonist at INR 2-3 | AstraZeneca | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vitamin-K antagonist at INR 2-3 CI watch — RSS
- Vitamin-K antagonist at INR 2-3 CI watch — Atom
- Vitamin-K antagonist at INR 2-3 CI watch — JSON
- Vitamin-K antagonist at INR 2-3 alone — RSS
Cite this brief
Drug Landscape (2026). Vitamin-K antagonist at INR 2-3 — Competitive Intelligence Brief. https://druglandscape.com/ci/vitamin-k-antagonist-at-inr-2-3. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab